Evidence map›Paper›PMID 41240094›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Meng Liang, Caozhe Cui, Xiaomeng Li, Jiancong Guo, Xinchao Wang, Yiyi Hu, Caixia Yan, Xiaoli Shi, Mengchun Li, Jianbo Cao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Meng LiangDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China.
Caozhe CuiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China.
Xiaomeng LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China.
Jiancong GuoDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China.
Xinchao WangDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China.
Yiyi HuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China.
Caixia YanDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China.
Xiaoli ShiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China.
Mengchun LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China.
Jianbo CaoDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China. caojianbo272@gmail.com.
Zhifang WuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85 South Jiefang Road Taiyuan, 030001, Shanxi, People's Republic of China. zhifangwu@sxmu.edu.cn.ORCID 0000-0003-0376-982X

Funding

Innovative Research Group Project of the National Natural Science Foundation of China 82027804
6 · The paper itself

Abstract

purposeThis study aimed to evaluate hypothalamic-pituitary-adrenal (HPA) axis activity in lung cancer patients using

methodsClinical data and

resultsLung cancer patients exhibited higher SUVmax, SUVmean, and MTV in adrenal glands; higher SUVmax and SUVmean in muscle and fat and higher SUVmean in gonads and pituitary compared to controls (P < 0.05). Hypermetabolism was observed in subthalamic nuclei, thalamus and amygdala, whereas hypometabolism was noted in frontal gyri and insula. Multivariate analysis identified right adrenal SUVmean (P = 0.048), fat SUVmax (P = 0.002) and total lesion glycolysis (TLG) (P = 0.036) as independent prognostic factors. In the mouse model, combination therapy improved body weight and motor function, and reduced glucose metabolism compared to chemotherapy (P < 0.05).

conclusions[ CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Fluorodeoxyglucose F18Hypothalamo-Hypophyseal SystemLung NeoplasmsPituitary-Adrenal SystemPositron Emission Tomography Computed TomographyA549 CellsAdultAgedAnimalsFemaleHumansMaleMiceMiddle AgedPrognosisRetrospective StudiesFluorodeoxyglucose F18FDGHPA axisLung cancerMusclePET/CTPrognosis

Identifiers

PMID41240094
PMCPMC12920370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.